title: Indomethacin to the rescue of TRAIL-resistant melanomas.
abstract: Patients with melanomas develop resistance to both conventional- and targeted-therapy drugs. Promising clinical responses with immune checkpoint reagents have resulted in renewed interest in the use of biological therapies, although only subsets of individuals are known to respond to these reagents. Tse et al. now report on the use of indomethacin, an anti-inflammatory drug, to sensitize therapy-resistant melanoma cells.
authors.affiliation: Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, USA. Electronic address: shyam@wistar.org.
authors.forename: Rajasekharan
authors.initials: R
authors.lastname: Somasundaram
authors.affiliation: Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, USA.
authors.forename: Meenhard
authors.initials: M
authors.lastname: Herlyn
mesh_terms: D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008545:Melanoma / Q000188:drug therapy*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy*; D000077022:Survivin; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D000077022:Survivin; D053221:TNF-Related Apoptosis-Inducing Ligand; C505639:TNFRSF10B protein, human; C505653:TNFSF10 protein, human; D007213:Indomethacin
references.citation: J Biol Chem. 2009 Jan 30;284(5):3058-3068
references.pmid: 19049974
references.citation: Am J Clin Oncol. 2012 Dec;35(6):606-11
references.pmid: 21336089
references.citation: Oncoimmunology. 2013 May 1;2(5):e24320
references.pmid: 23762807
references.citation: Cancer Med. 2013 Oct;2(5):662-73
references.pmid: 24403232
references.citation: Nat Rev Cancer. 2001 Nov;1(2):142-50
references.pmid: 11905805
references.citation: BMC Med. 2012 Mar 02;10:23
references.pmid: 22385436
references.citation: Am J Clin Exp Immunol. 2013 Feb 27;2(1):55-74
references.pmid: 23885325
references.citation: Nat Rev Drug Discov. 2006 Dec;5(12):997-1014
references.pmid: 17139285
references.citation: J Invest Dermatol. 2014 May;134(5):1397-1407
references.pmid: 24213373
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846
references.citation: N Engl J Med. 2013 Apr 4;368(14):1365-6
references.pmid: 23550685
references.citation: N Engl J Med. 2012 Jul 12;367(2):107-14
references.pmid: 22663011